Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-DOTA-4P(FAPI)4
- Development stage
- Preclinical
- Lead developer
- Xiamen University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[177Lu]Lu-DOTA-4P(FAPI)4 is a preclinical-stage radiolabeled fibroblast activation protein (FAP) inhibitor (FAPI) tetramer designed for targeted radioligand therapy of FAP-expressing tumors. Developed by researchers at Xiamen University, the agent utilizes a polyvalent tetrameric structure based on FAPI-46 conjugated to a DOTA chelator and radiolabeled with the beta-emitting radionuclide lutetium-177 (177Lu). By exploiting the polyvalency effect, the tetramer exhibits significantly higher tumor uptake, longer tumor retention, and slower clearance compared to its monomeric and dimeric counterparts. In preclinical models of FAP-positive tumors (such as HT-1080-FAP and U87MG xenografts), [177Lu]Lu-DOTA-4P(FAPI)4 demonstrated robust antitumor efficacy and tumor growth suppression.
- Other names
- 177Lu-DOTA-4P(FAPI)4177Lu-labeled FAPI tetramerlutetium Lu 177 DOTA-4P(FAPI)4lutetium-177 DOTA-4P(FAPI)4
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on [177Lu]Lu-DOTA-4P(FAPI)4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [177Lu]Lu-DOTA-4P(FAPI)4.